Opportunity Information: Apply for PA 07 385
Apply for PA 07 385
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Transfusion Related Acute Lung Injury (TRALI) Basic Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Dec 5, 2008 and posted on Jul 12, 2007.
- Applicants must submit their applications by Multiple Receipt Dates See Link to Full Announcement for details.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Foreign institutions are eligible to apply.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Transfusion Related Acute Lung Injury (TRALI) Basic Research (R01) opportunity (Funding Opportunity Number PA-07-385) is a National Institutes of Health grant announcement led by the National Heart, Lung, and Blood Institute (NHLBI). It is designed to support basic and mechanistic research focused on why some patients develop acute lung injury after receiving a blood transfusion. TRALI is a serious, sudden-onset complication that can occur following transfusion, and the announcement frames the public health importance in practical terms: roughly four million people receive transfusions each year in the United States, and a portion of these recipients may be at risk. The overall goal is to push the field beyond description of the syndrome and toward a clearer understanding of causation, which in turn can inform better ways to prevent TRALI, recognize it earlier, and treat it more effectively.
This program uses the NIH Research Project Grant (R01) mechanism, meaning it is intended for hypothesis-driven research projects with clearly defined aims, a solid scientific premise, and a plan that can produce publishable, generalizable advances in knowledge. While the announcement is focused on basic research, the emphasis is not purely academic; the expectation is that mechanistic insight will be leveraged to stimulate strategy development for prevention, diagnosis, and treatment. In other words, the work should illuminate the biological pathways and triggers that lead from transfusion exposure to acute lung injury, and ideally point to actionable interventions or diagnostic approaches that could reduce morbidity and mortality.
Funding under this announcement is not guaranteed year to year; awards are explicitly contingent on the availability of appropriated funds and on the Institute receiving a sufficient number of high-quality applications. The announcement also does not promise a set number of awards, which is common for NIH program announcements of this type. Instead, applications compete on scientific merit through the standard NIH peer review process, and only proposals judged both strong and programmatically relevant move forward for possible funding.
In terms of who can apply, eligibility is broad and includes public and state-controlled institutions of higher education, private universities, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, and small businesses. The listing also indicates that foreign institutions are eligible, which widens the applicant pool and reflects the global nature of transfusion medicine research. The opportunity is categorized as discretionary funding, issued as a grant, and aligns with NIH program areas under CFDA numbers 93.838 (Lung Diseases Research) and 93.839 (Blood Diseases and Resources Research, reflecting TRALI's intersection between pulmonary injury and transfusion-related blood resource issues).
Administratively, the FOA was posted on July 12, 2007, with multiple receipt dates rather than a single deadline, which typically allows investigators to apply during standard NIH submission cycles as long as the program announcement remains active. The archive date listed as October 8, 2010 indicates that the specific announcement is no longer active in its original form, but it remains useful as a reference point for how NHLBI framed TRALI research priorities during that period and what types of projects it sought to stimulate. The full text of the announcement is linked through the NIH Grants Guide (http://grants.nih.gov/grants/guide/pa-files/PA-07-385.html), and NIH Office of Extramural Research (OER) webmaster contacts are provided for access or technical linking issues.
TRALI Basic Research (R01) (PA-07-385) - Frequently Asked Questions
1) What is the Transfusion Related Acute Lung Injury (TRALI) Basic Research (R01) opportunity?
It is a National Institutes of Health (NIH) grant opportunity focused on basic and mechanistic research into why some patients develop acute lung injury after receiving a blood transfusion. The funding opportunity number is PA-07-385, and it is led by the National Heart, Lung, and Blood Institute (NHLBI).
2) Which NIH institute leads this funding opportunity?
The opportunity is led by the National Heart, Lung, and Blood Institute (NHLBI) within NIH.
3) What research topic is this FOA trying to advance?
The FOA is designed to support research that moves beyond describing TRALI as a syndrome and instead clarifies causation. The emphasis is on understanding the biological pathways and triggers that link transfusion exposure to acute lung injury.
4) Why does NIH describe TRALI as a public health issue?
The announcement frames the importance in practical terms: roughly four million people receive blood transfusions each year in the United States, and a portion of those recipients may be at risk for TRALI, which is described as a serious, sudden-onset complication following transfusion.
5) What is the overall goal of the program?
The overall goal is to generate mechanistic insight into TRALI that can inform better approaches to prevention, earlier recognition (diagnosis), and more effective treatment, ultimately aiming to reduce morbidity and mortality.
6) What grant mechanism does this program use?
This program uses the NIH Research Project Grant (R01) mechanism. It is intended for hypothesis-driven projects with clearly defined aims and a strong scientific premise.
7) Is this opportunity purely basic research, or does it also connect to clinical impact?
While the stated focus is basic and mechanistic research, the announcement emphasizes that mechanistic findings are expected to stimulate strategy development for prevention, diagnosis, and treatment. The intent is that biological understanding should point toward actionable interventions or diagnostic approaches.
8) What kinds of projects are considered a fit based on the description provided?
Projects that investigate the causative mechanisms of TRALI and the biological pathways and triggers that lead from transfusion exposure to acute lung injury are positioned as central. The FOA is oriented toward studies that can produce publishable, generalizable advances and help move the field toward causation and solutions.
9) How are applications reviewed and selected for possible funding?
Applications compete through the standard NIH peer review process and are evaluated on scientific merit. Proposals considered both scientifically strong and programmatically relevant may be considered for funding.
10) Does the FOA guarantee funding, a set number of awards, or annual support?
No. The announcement states that awards are contingent on the availability of appropriated funds and on the institute receiving a sufficient number of high-quality applications. It also does not promise a specific number of awards.
11) Who is eligible to apply?
Eligibility is broad and includes:
- Public and state-controlled institutions of higher education
- Private universities
- Nonprofit organizations (including those with and without 501(c)(3) status)
- For-profit organizations other than small businesses
- Small businesses
- Foreign institutions (listed as eligible)
12) Are foreign (non-U.S.) institutions eligible to apply?
Yes. The listing indicates that foreign institutions are eligible, reflecting the global nature of transfusion medicine research.
13) What type of funding is this categorized as?
The opportunity is categorized as discretionary funding and is issued as a grant.
14) What CFDA program areas are associated with this FOA?
The opportunity aligns with NIH program areas under CFDA numbers 93.838 (Lung Diseases Research) and 93.839 (Blood Diseases and Resources Research), reflecting TRALI's connection to both pulmonary injury and transfusion-related blood resource issues.
15) When was this FOA posted?
The FOA was posted on July 12, 2007.
16) Does this opportunity have a single deadline or multiple receipt dates?
The description indicates multiple receipt dates rather than a single deadline, which generally corresponds to applying during standard NIH submission cycles while the announcement remains active.
17) Is PA-07-385 still active?
The archive date is listed as October 8, 2010, which indicates the specific announcement is no longer active in its original form.
18) If it is archived, why might it still be useful?
The archived FOA remains useful as a reference for how NHLBI framed TRALI research priorities during that period and what types of projects it sought to stimulate.
19) Where can I find the full text of the announcement?
The full text is available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PA-07-385.html
20) Who should be contacted for access or technical issues with the link?
The description notes that NIH Office of Extramural Research (OER) webmaster contacts are provided for access or technical linking issues.
Browse more opportunities from the same category: Health
Next opportunity: Young Children with Mild to Severe Hearing Loss (R01)
Previous opportunity: Understanding and Treating Generalized and Focal Dystonias (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 07 385
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 07 385) also looked into and applied for these:
| Funding Opportunity |
|---|
| Young Children with Mild to Severe Hearing Loss (R01) Apply for PA 07 399 Funding Number: PA 07 399 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Young Children with Mild to Severe Hearing Loss (R21) Apply for PA 07 400 Funding Number: PA 07 400 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R01) Apply for PA 07 406 Funding Number: PA 07 406 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R21) Apply for PA 07 407 Funding Number: PA 07 407 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Screening and Brief Alcohol Interventions in Underage and Young Adult Populations (R03) Apply for PA 07 408 Funding Number: PA 07 408 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to the Doctorate Program (R25) Apply for PAR 07 410 Funding Number: PAR 07 410 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Bridges to the Baccalaureate Program (R25) Apply for PAR 07 411 Funding Number: PAR 07 411 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Small Grant Program for New Investigators (R03) Apply for PAR 07 418 Funding Number: PAR 07 418 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R01) Apply for PA 07 427 Funding Number: PA 07 427 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R21) Apply for PA 07 428 Funding Number: PA 07 428 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research on Alcohol Related Public Policies such as Those Detailed in the Alcohol Policy Information System (R03) Apply for PA 07 429 Funding Number: PA 07 429 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIGMS Postbaccalaureate Research Education Program (PREP) R25 Apply for PAR 07 432 Funding Number: PAR 07 432 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Interventions for Child Abuse and Neglect (R01) Apply for PA 07 437 Funding Number: PA 07 437 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiology and Prevention in Alcohol Research (R01) Apply for PA 07 448 Funding Number: PA 07 448 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Epidemiology and Prevention in Alcohol Research (R21) Apply for PA 07 449 Funding Number: PA 07 449 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Epidemiology and Prevention in Alcohol Research (R03) Apply for PA 07 450 Funding Number: PA 07 450 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Diversity Research Education Grants in Neuroscience (R25) Apply for PAR 07 456 Funding Number: PAR 07 456 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Technology and Methods Development for Genomics, Population Genomics and ELSI (R01) Apply for PA 07 458 Funding Number: PA 07 458 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Feasibility Studies to Develop Technology and Methods for Genomics, Population Genomics and ELSI (R21) Apply for PA 07 459 Funding Number: PA 07 459 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIAID Science Education Awards (R25) Apply for PAR 08 003 Funding Number: PAR 08 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 07 385", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.